HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: The first epigenetically targeted therapies to enter clinical practice include the histone deacetylase (HDAC) and DNA methyltransferase inhibitors [47], which have been approved for the treatment of cutaneous T cell lymphoma and myelodysplastic syndromes respectively, and are being actively investigated for other cancers.